Literature DB >> 27469434

Effects of high-frequency repetitive transcranial magnetic stimulation (rTMS) on spontaneously hypertensive rats, an animal model of attention-deficit/hyperactivity disorder.

Jungyun Kim1, Heamen Park1, Seong-Lan Yu2, Sungju Jee3, Keun-Ah Cheon4, Dong Ho Song4, Seung Jun Kim5, Woo-Young Im6, Jaeku Kang7.   

Abstract

The current treatment of choice for attention deficit hyperactivity disorder (ADHD) is pharmacotherapy. A search for new treatment options is underway, however, as the wide application of drugs to the general population of patients with ADHD is limited by side effects and the variance of pharmacokinetic effects of the drugs in each patient. In the present study, we applied repetitive transcranial magnetic stimulation (rTMS), a non-invasive treatment used in a number of other psychiatric disorders, to spontaneously hypertensive rats (SHRs), an animal model of ADHD, in order to assess the efficacy of the treatment in modifying behavioural symptoms as well as levels of dopamine, noradrenaline, serotonin, and brain-derived neurotrophic factor (BDNF). A total of fifteen sessions of high-frequency rTMS treatment were administered. Behavioural symptoms were observed using open field, Y-maze, and elevated plus-maze tests. Upon completion of the experiments, rats were sacrificed, and the neurochemical changes in brain tissue were analysed using high performance liquid chromatography and Western blotting. The SHRs treated with rTMS tended to exhibit less locomotor activity in the open field test over the course of treatment, but there was no improvement in inattention as measured by the Y-maze test. Furthermore, BDNF concentration increased and noradrenaline concentration decreased in the prefrontal cortex of SHRs treated with rTMS. The results of the present preclinical study indicate that rTMS may constitute a new modality of treatment for patients with ADHD, through further evaluation of specific treatment parameters as well as safety and efficacy in humans are required.
Copyright © 2016 ISDN. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Attention-deficit hyperactivity disorder (ADHD); Behavior analysis; Brain-derived neurotrophic factor (BDNF); Catecholamines; Repetitive transcranial magnetic stimulation (rTMS); Spontaneously hypertensive rat (SHR)

Mesh:

Substances:

Year:  2016        PMID: 27469434     DOI: 10.1016/j.ijdevneu.2016.07.006

Source DB:  PubMed          Journal:  Int J Dev Neurosci        ISSN: 0736-5748            Impact factor:   2.457


  3 in total

1.  Differential Behavioral and Biochemical Responses to Caffeine in Male and Female Rats from a Validated Model of Attention Deficit and Hyperactivity Disorder.

Authors:  Fernanda Nunes; Daniela Pochmann; Amanda Staldoni Almeida; Daniela Melo Marques; Lisiane de Oliveira Porciúncula
Journal:  Mol Neurobiol       Date:  2018-03-20       Impact factor: 5.590

Review 2.  Non-Invasive Brain Stimulation Effects on Biomarkers of Tryptophan Metabolism: A Scoping Review and Meta-Analysis.

Authors:  Cristian G Giron; Tim T Z Lin; Rebecca L D Kan; Bella B B Zhang; Suk Yu Yau; Georg S Kranz
Journal:  Int J Mol Sci       Date:  2022-08-26       Impact factor: 6.208

Review 3.  Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines.

Authors:  Simone Rossi; Andrea Antal; Sven Bestmann; Marom Bikson; Carmen Brewer; Jürgen Brockmöller; Linda L Carpenter; Massimo Cincotta; Robert Chen; Jeff D Daskalakis; Vincenzo Di Lazzaro; Michael D Fox; Mark S George; Donald Gilbert; Vasilios K Kimiskidis; Giacomo Koch; Risto J Ilmoniemi; Jean Pascal Lefaucheur; Letizia Leocani; Sarah H Lisanby; Carlo Miniussi; Frank Padberg; Alvaro Pascual-Leone; Walter Paulus; Angel V Peterchev; Angelo Quartarone; Alexander Rotenberg; John Rothwell; Paolo M Rossini; Emiliano Santarnecchi; Mouhsin M Shafi; Hartwig R Siebner; Yoshikatzu Ugawa; Eric M Wassermann; Abraham Zangen; Ulf Ziemann; Mark Hallett
Journal:  Clin Neurophysiol       Date:  2020-10-24       Impact factor: 4.861

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.